Biotech Daily Thursday July 16, 2015 Pharmaust says it has...

Biotech Daily
Thursday July 16, 2015

Pharmaust says it has completed the treatment with PPL-1 in combination with carboplatin
of two dogs with cancer.
Pharmaust said that neither dog suffered any adverse events despite the fact they both
had progressive, advanced cancers and few treatment options.
The company said that one of the dogs, treated with 5mg/kg PPL-1 in addition to
carboplatin, had stable disease for a short period.
Pharmaust executive chairman Dr Roger Aston said that combining chemotherapy with
PPL-1 in a target species with a natural cancer was “an important step”.
“Previous studies in rodents … showed highly significant synergy between chemotherapy
and PPL-1 without enhancement of the associated side-effects commonly seen with
anticancer drugs,” Dr Aston said.
“As such, the lack of any adverse events in canines is an exciting outcome,” Dr Aston
said.
“Furthermore, this gives us much confidence in moving forward with phase II combination
therapies in man,” Dr Aston said.
Pharmaust said that with the Sydney-based Veterinary Oncology Consultants it would
continue the recruitment and treatment of canine patients with combination therapy for the
possibility that the preliminary effects observed on stabilising progressive cancer in one of
the two dogs could be further evaluated.
Pharmaust fell 0.1 cents or 11.1 percent to 0.8 cents with 21.8 million shares traded.